Cellect Biotechnology (APOP)

[apollo1452]

From August earnings PR:
"company's cash ~$7.6M, 1st half burn ~$3.7M...our actions have significantly reduced our monthly cash burn & we believe that based on our current anticipated cash needs, our current cash burn rate gives us over 18 months of cash, sufficient to achieve our primary objective of reaching clinical results".

So this is why they haven't played the dilution card after the RS pps spike?

Also, APOP already signed Accelerated Clinical Trial Agreement with Washington University.

This ticker is new to me, comments welcome if you know what is happening with fundamentals on this one.